Efficacy and predictors of pegylated-interferon in hepatitis B surface antigen seroclearance in immune active and inactive chronic hepatitis B patients
PegIFN α-2b achieved clinically meaningful HBsAg seroclearance in both immune-inactive and immune-active patients. Early discontinuation markedly reduced real-world effectiveness. Baseline low HBsAg and dynamic on-treatment decline are pragmatic predictors for optimizing patient selection and guiding interferon-based strategies.
Authors
- Chao Han (ORCID: https://orcid.org/0000-0002-6869-0701)
- Zhihong Liu (ORCID: https://orcid.org/0000-0003-1142-3589)
- Xiaoyong Zhang (ORCID: https://orcid.org/0000-0002-6930-9423)
- Linlin Jin
- Guiping Li
- Qiuying Qin (ORCID: https://orcid.org/0009-0007-2549-9097)
- Mujia Zhu
Institutions
- Foshan Second People's Hospital (CN)
- Nanxi Mountain Hospital (CN)
- Guangdong Provincial Center for Disease Control and Prevention (CN)
- Southern Medical University (CN)
Publication Details
- Journal
- Journal of Virus Eradication
- Published
- 2025-11-20
- DOI
- https://doi.org/10.1016/j.jve.2025.100616
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00